News Search Results
Jun 10, 2025, 07:00 ET Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed
More news about: Anixa Biosciences, Inc.
Jun 10, 2025, 07:00 ET Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
first-in-class pan-mesenchymal cancer targeting ADC in phase 1/2 clinical development. About Adcendo Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.
More news about: Adcendo
Jun 10, 2025, 07:00 ET Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
first-in-class pan-mesenchymal cancer targeting ADC in phase 1/2 clinical development. About Adcendo Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.
More news about: Adcendo
Jun 10, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized
More news about: Bio-Techne Corporation
Jun 10, 2025, 06:00 ET Sanyou Biopharmaceuticals and Medicovestor, Inc. Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
R&D today announced the signing of a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs). The agreement, officially
More news about: Sanyou Bio
Jun 10, 2025, 06:00 ET Blue Water Acquisition Corp. III Announces the Upsized Pricing of $220 Million Initial Public Offering
business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the artificial intelligence (AI), biotechnology, healthcare and technology sectors. Forward-Looking Statements This press release contains statements that constitute "forward-looking
More news about: Blue Water Acquisition Corp iii
Jun 10, 2025, 04:49 ET Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
-- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Nuevocor
Jun 10, 2025, 04:15 ET Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
enhancing the overall treatment impact and long-term value." The BIO International Convention is the world's largest and most influential biotechnology event, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation
More news about: Caliway Biopharmaceuticals
Jun 10, 2025, 03:00 ET AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSilk4Care
commented: "With AMSilk4Shine and AMSilk4Care, we are pushing the boundaries of bio-based consumer care solutions by offering an affordable biotechnology ingredient that meets the growing demand for eco-conscious products – without compromising on performance. This marks an exciting step forward for
More news about: AMSilk
Jun 09, 2025, 15:12 ET ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
investment manager based in Austin, Texas, focused on public and private equity investments in the life sciences and biotechnology sectors. The firm was founded in October 2018 by Dr. Daniel Schneeberger, who brings
More news about: ADAR1 Capital Management, LLC
Jun 09, 2025, 14:00 ET Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma
Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U.S. Food and Drug Administration (FDA) has accepted
More news about: Myosin Therapeutics Inc.
Jun 09, 2025, 12:45 ET Formation Bio Announces First Class of Entrepreneurs in Residence to Drive Pipeline Growth and Strategic Partnerships
business development at Synageva Biopharma and Javelin Pharmaceuticals and helped launch the Entrepreneur in Residence program at the North Carolina Biotechnology Center. Over his career, John has executed more than $1 billion in transactions—including regional partnerships at
More news about: Formation Bio
Jun 09, 2025, 12:22 ET Rubin and Rudman's John McGivney Named a 2025 Top 20 Managing Partner by Massachusetts Lawyers Weekly
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Jun 09, 2025, 10:00 ET tcmc to Showcase Asia's Leading Cell & Gene Therapy CDMO Capabilities at BIO International Convention
Convention, June 16-19. Often referred to as the 'TSMC of the CGT industry,' tcmc's presence at this premier global biotechnology event underscores its pivotal role in driving CGT innovation from Asia to the world.
More news about: tcmc
Jun 09, 2025, 09:00 ET Sequentify and Bio Molecular Systems Partner to Release InfiniSeq™ Myra Protocol for Automated NGS Library Preparation
https://www.sequentify.com/. About BMS: Bio Molecular Systems (BMS) is a biotechnology company that designs, manufactures and distributes instrumentation for the life sciences. Established in 2010 and composed of the founders and senior
More news about: Sequentify
Jun 09, 2025, 08:05 ET Psilera Collaborates with Drug Development Leader Hesperos to Advance Preclinical Modeling of PSIL-006 for Frontotemporal Dementia
Fla., June 9, 2025 /PRNewswire/ -- Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders and Hesperos Inc., a leader in organ-on-a-chip technology,
More news about: Psilera, Inc
Jun 09, 2025, 08:00 ET Neowise Biotechnology and BeOne Medicines Enter Licensing Agreement to Advance Development of Next-Generation Cell Therapies
therapies that expand and elevate treatment options for patients worldwide." About Neowise BiotechnologyNeowise Biotechnology (Suzhou) Co., Ltd. is an innovative biotechnology company focused on the development of TCR-T cell therapies for solid tumors. The company has built a high-throughput
More news about: Neowise Biotechnology
Jun 09, 2025, 08:00 ET CS Analytical to Serve as Bronze Level Sponsor Contract Pharma 2025 Contracting & Outsourcing Conference
cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to package and container testing for the pharmaceutical, biotechnology, and medical device industries is excited to announce that it will serve as Bronze Level Sponsor for the 2025 Contract Pharma Contracting and Outsourcing
More news about: CS Analytical
Jun 09, 2025, 08:00 ET Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic
More news about: Anixa Biosciences, Inc.
Jun 09, 2025, 07:45 ET FTRE INVESTOR ALERT: Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
global clinical research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. According to the complaint, in June 2023, Labcorp Holdings Inc. spun off Fortrea as
More news about: Robbins Geller Rudman & Dowd LLP
Jun 09, 2025, 07:30 ET Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
and Elaine Sun, the Board would be deprived of essential strategic leadership, vaccine expertise, senior public biotechnology and M&A experience, as well as deep industry financial expertise – qualifications that none of Deep Track's candidates can adequately match.
More news about: Dynavax Technologies
Jun 09, 2025, 07:00 ET COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
collagen (rhCollagen) for tissue regeneration and medical aesthetics, today announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine,
More news about: CollPlant
Jun 09, 2025, 07:00 ET Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
Full Prescribing Information. About Formosa Pharmaceuticals Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation
More news about: Formosa Pharmaceuticals Inc.
Jun 09, 2025, 06:10 ET WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu
(PGHD). In addition to this landmark partnership, the company has also established strategic partnership with industry-leading biotech firm Virogen Biotechnology. These collaborations — centered around commercial manufacturing operations — underscore WuXi Biologics' expanding portfolio of partnerships and
More news about: WuXi Biologics
Jun 09, 2025, 06:00 ET TORL BioTherapeutics Announces Appointment of Anna Berkenblit, MD, MMSc, as Board Member
June 9, 2025 /PRNewswire/ -- TORL BioTherapeutics LLC (TORL), a clinical-stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced
More news about: TORL Biotherapeutics LLC